Which drug, and when, for patients with BRAF-mutant melanoma?

[1]  R. Sullivan,et al.  A single center experience with high-dose (HD) IL-2 treatment for patients with advanced melanoma and pilot investigation of a novel gene expression signature as a predictor of response. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Hauschild,et al.  Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. , 2012, The Lancet. Oncology.

[3]  K. Flaherty,et al.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.

[4]  A. Ribas,et al.  Phase IB Study of Vemurafenib in Combination with the Mek Inhibitor, GDC-0973, in Patients (PTS) with Unresectable or Metastatic BRAFV600 Mutated Melanoma (BRIM7) , 2012 .

[5]  A. Hauschild,et al.  Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.

[6]  A. Hauschild,et al.  Management of immune-related adverse events and kinetics of response with ipilimumab. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Utikal,et al.  Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.

[8]  J. Emile,et al.  Prognostic Value of BRAFV600 Mutations in Melanoma Patients After Resection of Metastatic Lymph Nodes , 2012, Annals of Surgical Oncology.

[9]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[10]  Dirk Schadendorf,et al.  Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group , 2012 .

[11]  P. Ascierto,et al.  Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use , 2012, Journal of Translational Medicine.

[12]  A. Giobbie-Hurder,et al.  Outcomes of patients with malignant melanoma treated with immunotherapy prior to or after vemurafenib. , 2012 .

[13]  J. Wolchok,et al.  Ipilimumab (Ipi) expanded access program (EAP) for patients (pts) with stage III/IV melanoma: 10 mg/kg cohort interim results. , 2012 .

[14]  A. Hauschild,et al.  Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma . , 2012 .

[15]  M. Brown,et al.  Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial , 2012, The Lancet.

[16]  J. Wolchok,et al.  Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. , 2012, The Lancet. Oncology.

[17]  K. Flaherty,et al.  From genes to drugs: targeted strategies for melanoma , 2012, Nature Reviews Cancer.

[18]  Alison P. Klein,et al.  Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape , 2012, Science Translational Medicine.

[19]  Yu Shyr,et al.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.

[20]  D. Schadendorf,et al.  RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  K. Flaherty,et al.  RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. , 2012, The New England journal of medicine.

[22]  S. Nelson,et al.  Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance , 2012, Nature Communications.

[23]  R. Sullivan,et al.  Correlation of NRAS Mutations With Clinical Response to High-dose IL-2 in Patients With Advanced Melanoma , 2012, Journal of immunotherapy.

[24]  J. Wilmott,et al.  Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma , 2011, Clinical Cancer Research.

[25]  Tom Misteli,et al.  RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) , 2011, Nature.

[26]  A. Ribas,et al.  Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. , 2011, Cancer research.

[27]  Nikhil Wagle,et al.  Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  S. Ariyan,et al.  Melanoma brain metastases: is it time to reassess the bias? , 2011, Current problems in cancer.

[29]  K. Flaherty,et al.  BRAF targeted therapy changes the treatment paradigm in melanoma , 2011, Nature Reviews Clinical Oncology.

[30]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[31]  Axel Hoos,et al.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.

[32]  K. Flaherty,et al.  Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  R. Dummer,et al.  An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  S. Chasalow,et al.  Assessment of association between BRAF mutation status in melanoma tumors and response to ipilimumab. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  H. Ott,et al.  Abstract 958: Treatment with a selective inhibitor of BRAFV600E increases melanocyte antigen expression and CD8 T cell infiltrate in tumors of patients with metastatic melanoma , 2011 .

[36]  G. Mann,et al.  Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[38]  B. Comin-Anduix,et al.  The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations , 2010, Clinical Cancer Research.

[39]  Damien Kee,et al.  Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. , 2010, Cancer cell.

[40]  Marc Vidal,et al.  COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation , 2010, Nature.

[41]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[42]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[43]  K. Flaherty,et al.  Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. , 2010, Cancer research.

[44]  Axel Hoos,et al.  Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.

[45]  A. Maraveyas,et al.  A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma , 2009, Clinical Cancer Research.

[46]  Miriam V. Liscovsky,et al.  Interferon‐γ priming is involved in the activation of arginase by oligodeoxinucleotides containing CpG motifs in murine macrophages , 2009, Immunology.

[47]  John A Thompson,et al.  Treatment of metastatic melanoma: an overview. , 2009, Oncology.

[48]  M. Tretiakova,et al.  Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. , 2009, Cancer research.

[49]  V. Sondak,et al.  Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Grou , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  Kam Y. J. Zhang,et al.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.

[51]  R. Marais,et al.  Melanoma biology and new targeted therapy , 2007, Nature.

[52]  Drew M. Pardoll,et al.  Immunostimulatory monoclonal antibodies for cancer therapy , 2007, Nature Reviews Cancer.

[53]  Y. Kawakami,et al.  The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells , 2006, The Journal of experimental medicine.

[54]  J. Fridlyand,et al.  Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.

[55]  D. Tuveson,et al.  Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. , 2005, Cancer research.

[56]  H. Varmus,et al.  Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.

[57]  J. Kirkwood,et al.  Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? , 2004, European journal of cancer.

[58]  M. Gore,et al.  Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  J. Becker,et al.  Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis , 2004, Journal of carcinogenesis.

[60]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[61]  D. Keskin,et al.  Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase , 2002, Science.

[62]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[63]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[64]  E. Rofstad,et al.  Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. , 2000, Cancer research.

[65]  R. Fisher,et al.  High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  K. Flaherty,et al.  New options and new questions: how to select and sequence therapies for patients with metastatic melanoma. , 2012, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[67]  D. Schadendorf,et al.  Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.